Inferra AI / Company / AZTA
Azenta, Inc.
AZTA · Health Care
Last earnings Aug 4, 2026
Key results
Revenuequarter
0 %
Revenue from Continuing Operations $ 144 $ 143 $ 144 0 % (0 )% Organic growth (2 )% Sample Management Solutions $ 78 $ 80 $ 81 (3 )% (4 )% Multiomics $ 66 $ 64 $ 64 4 % 4 % Diluted EPS Continuing Operations $ 0.01 $ (0.40 ) $ (0.00 ) NM NM Diluted EPS Total $ (1.15 ) $ (0.88 ) $ (0.12 ) (30 )% NM Non-GAAP Diluted EPS Continuing Operations $ 0.19 $ 0.05 $ 0.14 NM 31 % Adjusted EBITDA - Continuing Operations $ 18 $ 14 $ 14 24 % 27 % Adjusted EBITDA Margin - Continuing Operations 12.3 % 10.0 % 9.7 % Management Comments We've made significant changes across the organization and our operational turnaround is progressing as planned.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Continuing Operations revenuequarter
$144 million
Third Quarter Fiscal 2025 Results - Continuing Operations Revenue was $144 million, flat year over year.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Sample Management Solutions revenuequarter
$78 million
Sample Management Solutions revenue was $78 million, down 4% year over year.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Growthquarter
down 4%
Sample Management Solutions revenue was $78 million, down 4% year over year.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Organic revenuequarter
6%
o Organic revenue declined 6%, driven by lower revenues in Core Products, particularly in Automated Stores and Cryogenic Systems, partially offset by higher revenue in Sample Storage, Clinical Biostores and Product Services.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Multiomics revenuequarter
$66 million
Multiomics revenue was $66 million, up 4% year over year.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
o Organic revenue grew 3% year over year, primarily driven by growth in Next Generation Sequencing, partially offset by a year-over-year decline in Sanger Sequencing and Gene Synthesis.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Operating marginquarter
0.5%
Operating margin was (0.5%), up 440 basis points year over year.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Gross marginquarter
47.1%
o Gross margin was 47.1%, up 170 basis points year over year, mainly driven by favorable sales mix, operating efficiencies, and improved cost execution.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
AI analysis
Q3 FY2025 · reported Aug 5, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Segment mix
Business-unit revenue, as stated
Segment revenue figures as stated in the event record.
Headline figures
| Metric | Q3 FY2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | 0 % | — | — |
| Continuing Operations revenue | $144 million | — | — |
| Sample Management Solutions revenue | $78 million | — | — |
| Growth | down 4% | — | — |
| Organic revenue | 6% | — | — |
| Multiomics revenue | $66 million | — | — |
| Operating margin | 0.5% | — | — |
| Gross margin | 47.1% | — | — |
Guidance · company-stated
Direction: Reiterated
“Guidance for Continuing Operations for Full Year Fiscal 2025 The Company is reiterating its guidance for fiscal year 2025: o Total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024.”
“htm Exhibit 99.1 Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025 ; Reiterates Full Year Fiscal 2025 Guidance BURLINGTON, Mass.”
Classified from the release's primary full-year outlook statement.
Margin
Capital allocation
Capital expenditures were $11 million, and free cash flow (cash flow from operations less capital expenditures) was $15 million.
Event summary
Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025 ; Reiterates Full Year Fiscal 2025 Guidance
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Reiterated
Revenue: “Guidance for Continuing Operations for Full Year Fiscal 2025 The Company is reiterating its guidance for fiscal year 2025: o Total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024.”
Company outlook — Reiterated (“Reiterates”)
“htm Exhibit 99.1 Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025 ; Reiterates Full Year Fiscal 2025 Guidance BURLINGTON, Mass.”
Revenue — Reiterated (“reiterating”)
“Guidance for Continuing Operations for Full Year Fiscal 2025 The Company is reiterating its guidance for fiscal year 2025: o Total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Capital expenditures were $11 million, and free cash flow (cash flow from operations less capital expenditures) was $15 million.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, non-recurring costs related to the Company s business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
The Vendor Loan Agreement was entered into on July 1, 2026 to support and facilitate the completion of the B Medical Transaction through a $ 35.0 million secured term loan from the Company s wholly-owned subsidiary, Azenta Germany GmbH, to Thelema.
SEC original ↗Azenta, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The Company also evaluated the fair value of the $ 35.0 million secured term loan under the Vendor Loan Agreement and concluded that the principal amount thereof approximated fair value of the loan as of the closing date, considering the contractual terms of the loan, the expected repayment period, borrower credit risk, and the estimated value of the underlying collateral.
SEC original ↗Azenta, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
Despite a challenging macro environment, we drove meaningful margin expansion through disciplined cost management and focused execution, said John Marotta, President and CEO.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
We remain on track to meet our full-year goals and are confident that the foundation we are building will support our long-term strategy.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
o Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2024.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, non-recurring costs related to the Company s business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
(2) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Risks & headwinds
These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta s financial and business results to differ materially from our expectations.
SEC original ↗Azenta, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Legal Proceedings 56 Item 1A.
SEC original ↗Azenta, Inc. — 10-Q Quarterly report10-QAug 6, 2026
These forward-looking statements are based on current expectations and involve risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied.
SEC original ↗Azenta, Inc. — 10-Q Quarterly report10-QAug 6, 2026
This data involves assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the 2025 Annual Report on Form 10-K and those described in this Quarterly Report on Form 10-Q under Information Related to Forward-Looking Statements above and Part II, Item 1A Risk Factors below, as updated and/or supplemented in subsequent filings with the SEC.
SEC original ↗Azenta, Inc. — 10-Q Quarterly report10-QAug 6, 2026
In addition, in January 2023, Edwards filed a lawsuit against the Company in the Supreme Court of the State of New York in the County of New York seeking indemnification from the Company under such definitive agreement for $ 1.0 million and other related damages, including interest and attorney s fees, arising from a third-party claim that was included as part of their initial claims (the 2023 Claim ).
SEC original ↗Azenta, Inc. — 10-Q Quarterly report10-QAug 6, 2026
During the third quarter of fiscal year 2023, the Company and Edwards entered into a settlement agreement related to the 2023 Claim to avoid the costs and uncertainties of potential litigation.
SEC original ↗Azenta, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
30 documents- Q3 2026
- 8-KAZTA
Oct 7, 2026
- Q2 2026
- 8-KAZTA
Sep 17, 2026
- 8-KAZTA
Sep 4, 2026
- 8-KAZTA
Aug 24, 2026
- 8-KAZTA
Aug 11, 2026
- 10-QAZTA
Aug 6, 2026
- 8-KAZTA
Aug 4, 2026
- 8-KAZTA
Jul 8, 2026
- Q1 2026
- 10-QAZTA
May 8, 2026
- 8-KAZTA
May 5, 2026
- 8-KAZTA
Apr 7, 2026
- 8-KAZTA
Apr 2, 2026
- Q4 2025
- 8-KAZTA
Mar 4, 2026
- 10-QAZTA
Feb 5, 2026
- 8-KAZTA
Feb 4, 2026
- 8-KAZTA
Feb 2, 2026
- 8-KAZTA
Jan 29, 2026
- Q3 2025
- 8-KAZTA
Dec 29, 2025
- 8-KAZTA
Dec 10, 2025
- 10-KAZTA
Dec 4, 2025
- 8-KAZTA
Nov 21, 2025
- Q2 2025
- 10-QAZTA
Aug 6, 2025
- 8-KAZTA
Aug 5, 2025
- 8-KAZTA
Jul 2, 2025
- Q1 2025
- 8-KAZTA
May 16, 2025
- 10-QAZTA
May 9, 2025
- 8-KAZTA
May 7, 2025
- 8-KAZTA
Apr 9, 2025
- Q4 2024
- 10-QAZTA
Feb 10, 2025
- 8-KAZTA
Feb 5, 2025
Earnings releases
10 documentsPresentations
0 documentsNo presentations for Azenta, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Azenta, Inc. are held in this edition of the library.
Mentioned by
1 companyOther tracked companies whose held documents mention Azenta, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
“nce leader, and its acquisition by Merck KGaA in 2010. Dr. Madaus serves on the boards of Azenta, Inc. and Hologic, Inc. He holds a…”
See also the earnings calendar for every tracked company’s next earnings date.